05.17.10
NeoPharm, Inc.’s IL13-PE38QQR (IL13-PE) has been granted orphan drug designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Orphan drug designation provides seven years of market exclusivity for IPF upon approval, as well as a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user fees and certain tax credits.
Dr. Aquilur Rahman, president and chief executive officer, said, “IPF is the most deadly disease of the lungs in humans with very high morbidity. It is estimated that about 55,000 patients are diagnosed with the disease and almost 45,000 of them die with this disease every year in the U.S. There is currently no proven effective treatment to cure this disease. All the studies that NeoPharm has performed in animals and in ex vivo human tissue have shown quite promising results. We look forward to starting our clinical studies with IL13-PE as aerosolized product in humans inflicted with this devastating disease quite soon.”
Orphan drug designation provides seven years of market exclusivity for IPF upon approval, as well as a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user fees and certain tax credits.
Dr. Aquilur Rahman, president and chief executive officer, said, “IPF is the most deadly disease of the lungs in humans with very high morbidity. It is estimated that about 55,000 patients are diagnosed with the disease and almost 45,000 of them die with this disease every year in the U.S. There is currently no proven effective treatment to cure this disease. All the studies that NeoPharm has performed in animals and in ex vivo human tissue have shown quite promising results. We look forward to starting our clinical studies with IL13-PE as aerosolized product in humans inflicted with this devastating disease quite soon.”